<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101264860</journal-id><journal-id journal-id-type="pubmed-jr-id">32902</journal-id><journal-id journal-id-type="nlm-ta">Obesity (Silver Spring)</journal-id><journal-id journal-id-type="iso-abbrev">Obesity (Silver Spring)</journal-id><journal-title-group><journal-title>Obesity (Silver Spring, Md.)</journal-title></journal-title-group><issn pub-type="ppub">1930-7381</issn><issn pub-type="epub">1930-739X</issn></journal-meta><article-meta><article-id pub-id-type="pmid">23505172</article-id><article-id pub-id-type="pmc">3499683</article-id><article-id pub-id-type="doi">10.1002/oby.20235</article-id><article-id pub-id-type="manuscript">NIHMS378375</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Malin</surname><given-names>Steven K.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nightingale</surname><given-names>Joy</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Sung-Eun</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chipkin</surname><given-names>Stuart R.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Braun</surname><given-names>Barry</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Energy Metabolism Laboratory, Department of Kinesiology, University of Massachusetts, Amherst, MA 01003</aff><aff id="A2"><label>2</label>Department of Family, Nutrition, and Exercise Sciences, Queens College, Flushing, NY</aff><author-notes><corresp id="CR1"><bold>Correspondence to:</bold> Barry Braun, PhD Dept. of Kinesiology 107 Totman Building University of Massachusetts Amherst, MA 01003 Phone: (413) 577-0146 Fax: (413) 545-2906 <email>bbraun@kin.umass.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>18</day><month>7</month><year>2012</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>05</day><month>11</month><year>2013</year></pub-date><volume>21</volume><issue>1</issue><fpage>93</fpage><lpage>100</lpage><!--elocation-id from pubmed: 10.1002/oby.20235--><permissions><license xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms"><license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p></license></permissions><abstract><p id="P1">Impaired glucose tolerant (IGT) adults are at elevated risk for cardiovascular disease (CVD). Exercise or metformin reduce CVD risk, but the efficacy of combining treatments is unclear. To determine the effects of exercise training plus metformin, compared to each treatment alone, on CVD risk factors in IGT adults. Subjects were assigned to: placebo (P), metformin (M), exercise plus placebo (EP), or exercise plus metformin (EM) (8/group). In a double-blind design, P or 2000mg/d of M were administered for 12 weeks and half performed aerobic and resistance training 3 days/week for approximately 60 minutes/day at 70% pre-training heart rate peak. Outcomes included: adiposity, blood pressure (BP), lipids and high sensitivity C-reactive protein (hs-CRP). Z-scores were calculated to determine metabolic syndrome severity. M and EM, but not EP, decreased body weight compared to P (p &#x0003c;0.05). M and EP lowered systolic BP by 6% (p &#x0003c; 0.05), diastolic BP by 6% (p &#x0003c; 0.05), and hs-CRP by 20% (M: trend p = 0.06; EP: p &#x0003c; 0.05) compared to P. Treatments raised HDL-cholesterol (p &#x0003c; 0.05; EM: trend p = 0.06) compared to P and lowered triacyglycerol (p &#x0003c; 0.05) and metabolic syndrome Z-score compared to baseline (EP; trend p = 0.07 and EM or M; p &#x0003c; 0.05). Although exercise and/or metformin improve some CVD risk factors, only training or metformin alone lowered hs-CRP and BP. Thus, metformin may attenuate the effects of training on some CVD risk factors and metabolic syndrome severity in IGT adults.</p></abstract><kwd-group><kwd>Prediabetes</kwd><kwd>Metabolic Syndrome</kwd><kwd>Type 2 Diabetes</kwd><kwd>Obesity</kwd><kwd>Hypertension</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p id="P2">Individuals with impaired glucose tolerance (IGT) are at elevated risk for cardiovascular disease (CVD) (<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>) and approximately half of these individuals have metabolic syndrome (i.e. hypertensive, hyperglycemic, and dyslipidemic) (<xref rid="R3" ref-type="bibr">3</xref>). CVD risk is largely explained by insulin resistance and excess body weight (<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>). Treatments that raise insulin sensitivity or lower body weight may lower CVD risk in individuals with IGT.</p><p id="P3">The mechanisms by which exercise lowers CVD risk likely involve increasing insulin sensitivity (<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R8" ref-type="bibr">8</xref>) and lowering circulating lipids (e.g. triacylglycerol, low-density lipoproteins, etc.), blood pressure, and C-reactive protein (<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>). Metformin treatment can also increase insulin sensitivity (<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R13" ref-type="bibr">13</xref>) and additionally, reduces fasting hyperglycemia and body weight (<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref>). Because the actions of exercise and metformin are potentially additive, it has been suggested that individuals with IGT and at least 1 CVD risk factor (e.g. hypertension, elevated triacylglycerol, low HDL, fasting hyperglycemia, etc.) be considered for metformin treatment while participating in a regular exercise program (<xref rid="R16" ref-type="bibr">16</xref>). However, the interactions between exercise and metformin on CVD risk factors have not been systematically evaluated (<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>). Adding to the uncertainty, we recently showed that metformin blunted the effects of training on insulin sensitivity in men and women with IGT (<xref rid="R19" ref-type="bibr">19</xref>). Since insulin resistance is believed to be a key underlying factor causing metabolic syndrome (formerly syndrome X), it is important to understand the effects of metformin on CVD risk after exercise training (<xref rid="R20" ref-type="bibr">20</xref>). Therefore, the purpose of this study was to determine the effects of combining metformin with exercise training, compared to either treatment alone, on reducing CVD risk factors in men and women with IGT. Given the opposing effects on insulin sensitivity we observed in this same study group (<xref rid="R19" ref-type="bibr">19</xref>), we hypothesized that the combined treatment would oppose the reduction in CVD risk compared to either treatment alone.</p></sec><sec sec-type="methods" id="S2"><title>Methods</title><sec id="S3"><title>Overview</title><p id="P4">The effects of exercise training, metformin, or the combined treatment on cardiovascular disease (CVD) risk factors were compared in 32 otherwise healthy men and women with impaired glucose tolerance (IGT). Using a double-blind, placebo-controlled design, individuals were tested before and after 12 weeks of placebo (P), metformin (M), exercise training plus placebo (EP) or exercise training plus metformin (EM). Outcome measures included body weight, waist circumference, blood pressure, and concentrations of blood lipids, and high sensitivity C-reactive protein (hs-CRP) as well as metabolic syndrome severity.</p></sec><sec sec-type="subjects" id="S4"><title>Subjects</title><p id="P5">These subjects were the same individuals who served as the study population in our prior study on whole-body and hepatic insulin sensitivity (<xref rid="R19" ref-type="bibr">19</xref>). Subjects were recruited via newspaper advertisements and flyers posted in the local community. Individuals (see <xref ref-type="table" rid="T1">Table 1</xref>) were non-smoking, weight stable (&#x0003c;5% weight change over last 3 months) and free of CVD or type 2 diabetes. All subjects had impaired glucose tolerance (IGT). Individuals who were using medications to manage blood pressure (M = 1; EP = 1; EM = 3) or cholesterol (M = 1; EP = 1; EM = 1) were enrolled and continued treatment throughout the study. Subjects were excluded from the study if they had any contraindications to metformin use (e.g. respiratory disease, heart failure, renal/hepatic disease). All subjects were verbally briefed about the study and signed informed consent documents approved by the Institutional Review Board at the University of Massachusetts Amherst.</p></sec><sec id="S5"><title>Screening</title><p id="P6">A 75 gram oral glucose tolerance test (OGTT) was used to screen individuals for IGT after a minimum 5 hour fast. Individuals with glucose concentrations between 7.8&#x02013;11.1mM (140&#x02013;199mg/dl) 120 minutes after consuming glucose met the criterion for IGT. Approximately half of the subjects with IGT also had impaired fasting glucose (IFG), i.e. fasting glucose concentrations between 5.5&#x02013;6.9mM (100&#x02013;125mg/dl). Most of the individuals in each treatment group (M = 6; EP = 7 and EM = 6) also met ATP III criteria for metabolic syndrome (<xref rid="R21" ref-type="bibr">21</xref>). Only 2 participants in the P group had metabolic syndrome. To minimize the potential for Type-1 and Type-2 errors, we restricted the presentation of results to the 3 treatment groups</p></sec><sec id="S6"><title>Exercise testing</title><p id="P7">VO<sub>2</sub>peak was used to characterize cardiorespiratory fitness, and 1-repetition max (1-RM) tests were performed to determine strength as previously described (<xref rid="R19" ref-type="bibr">19</xref>).</p></sec><sec id="S7"><title>Metformin or placebo protocol</title><p id="P8">A member of the research group, blinded to the protocol, administered pills to the subjects. All subjects were instructed to take their pills with food to minimize potential side effects. Subjects started treatment with 500 mg/d of metformin. The dose was increased 500 mg/d each week until a standard clinical dose of 2000 mg/d was reached by week 4. This dose was maintained for the ensuing 8 weeks of the protocol.</p></sec><sec id="S8"><title>Exercise training</title><p id="P9">Subjects underwent supervised exercise sessions 3 days/week for 60&#x02013;75 minutes per session (approximately 190minutes/week total). Subjects cycled for 45 minutes at 70% of their pre-training heart rate peak 3days/week, and performed whole-body resistance exercise at 70% of the subject's 1-RM 2days/week. Subjects performed 2 sets of 12 repetitions for: chest press, latissimus pull down, leg press, bicep curl, triceps pushdown, and upright rows. Pedometers (Omron HJ112, Lake Forest, IL) were provided to all subjects and worn around the waistband for 7 consecutive days at week 0, 6 and 12. These data were averaged to characterize habitual ambulation. Habitual ambulation did not change in any group after the intervention, nor were there differences across groups (data not shown).</p></sec><sec id="S9"><title>Body weight, composition &#x00026; waist circumference</title><p id="P10">Body weight was recorded without shoes, to the nearest 0.1kg on a calibrated scale, every 2 weeks at consistent times of day. Subjects were weighed in the fasted state for the first and last measurements. As previously described (<xref rid="R19" ref-type="bibr">19</xref>) body fat and central fat (defined as fat mass in the region bounded by the last floating rib to the top of the iliac crest/total fat mass) were assessed by Dual-energy x-ray absorptiometry (DEXA; Lunar Prodigy, Madison, WI). Waist circumference (WC) was measured to the nearest 0.25 cm with a plastic tape measure in the standing position approximately 2 cm above the umbilicus.</p></sec><sec id="S10"><title>Food intake</title><p id="P11">Food intake was assessed using 3-day food records at week 0, 6, and 12. Subjects selected 3 days of the week at the start of the study and the same 3 days of the week were used each time food intake was assessed. Results were averaged across the 3 days to generate a single value for energy intake at each time point. Participants were given verbal and written instructions to accurately record the types and quantities of all food and beverages consumed, including brand names and methods of food preparation. Food records were analyzed (by the same investigator S.C.) using a commercial software program (Fitday, El Segundo, California).</p></sec><sec id="S11"><title>Blood pressure, lipids and high sensitivity-CRP</title><p id="P12">Subjects were provided isocaloric meals (~55% carbohydrate, 30% fat, and 15% protein multiplied by 1.3 activity factor) 24 hours before baseline and week 12 measurements. Energy intake was based on resting metabolic rate measurements for 30 minutes in the supine position by indirect calorimetry (SensorMedics 800, Yorba Linda, CA). On the day of testing, subjects reported to the laboratory after an overnight fast. Systolic (SBP) and diastolic (DBP) blood pressure was determined once in the left arm using an automated system (Mark of Fitness, Inc., Shrewsbury, NJ) after at least 5&#x02013;10 minutes of quiet sitting. Next, indwelling catheters were placed in a superficial vein of the forearm and fasting blood samples were collected in 3 mL syringes. All vacutainers were kept on ice prior to blood collection. Blood samples for the analysis of glucose were transferred to vacutainers containing sodium fluoride to inhibit glycolysis. Blood samples for the analysis of total cholesterol (TC), high-density lipoproteins (HDL), and triacylglycerol (TAG) were collected in vacutainers containing the anticoagulant EDTA. Serum samples for the analysis of hs-CRP were collected in vacutainers containing a serum separator and allowed to clot for 15 minutes. Blood samples were centrifuged at room temperature for 10 minutes at 3000 RPM. Samples were immediately aliquoted and transferred to a &#x02212;80&#x000b0;C freezer until analysis.</p></sec><sec id="S12"><title>Biochemical analyses</title><p id="P13">Fasting Plasma glucose (FPG), TC and HDL concentrations were determined enzymatically (GL5 Analyzer, Analox Instruments, Lunenberg, MA). TAG concentrations were measured by colorimetric assay (Sigma Aldrich, St. Louis, MO). Serum hs-CRP concentrations were measured using high-sensitivity ELISA kit (Diagnostic Systems Laboratory, Webster, TX). Calculations: Mean arterial pressure (MAP) was calculated as: MAP = (2/3DBP) + (1/3SBP). The cardiac risk ratio (CRR) was calculated as TC divided by HDL (<xref rid="R19" ref-type="bibr">19</xref>). Low density lipoprotein (LDL) was calculated using the Friedwald equation (LDL = TC &#x02013; HDL &#x02013; (TAG* 0.2) (<xref rid="R20" ref-type="bibr">20</xref>). Metabolic syndrome Z-scores and ATP III criteria were calculated to describe the efficacy of each treatment on metabolic syndrome severity and total number of risk factors (<xref rid="R18" ref-type="bibr">18</xref>). Sex specific Z-scores were calculated as: male Z-score = [(40-HDL)/10.7] + [(TAG-150/88.5)] + [(FPG-100)/11.9] + [(WC-102)/14.3] + [(MAP-100)/8.8], and female Z-score = [(50-HDL)/11.0] + [(TAG-150/88.5)] + [(FPG-100)/11.9] + [(WC-88)/13.6] + [(MAP-100)/8.8].</p></sec><sec id="S13"><title>Statistical Analysis</title><p id="P14">Data were analyzed using the R statistical software package (version 2.4.0, The R foundation, Vienna, Austria, 2006). Baseline subject characteristics were measured across conditions by one-way analysis of variance (ANOVA). There was no statistical difference in any baseline value except DBP. Using baseline DBP as a co-variate did not affect the response to the treatments. All other condition means were analyzed before and after the intervention using 2-way (condition by test) repeated measures ANOVA. Because baseline hs-CRP concentrations were not normally distributed, the data were log transformed for statistical analysis. When there was a significant condition &#x000d7; test interaction, Tukey's Post hoc analysis was used to detect differences across conditions. Paired t-tests were used to assess pre- to post differences within a condition, including caloric intake, metabolic syndrome Z-score and ATP III score. McNemar's test was used to assess metabolic syndrome prevalence (i.e. yes/no) after each treatment (<xref rid="R22" ref-type="bibr">22</xref>). Pearson's correlation was used to examine relationships between weight loss, cardiorespiratory fitness, CVD risk factors and insulin sensitivity (<xref rid="R19" ref-type="bibr">19</xref>). Significant differences were accepted as &#x003b1; &#x02264; 0.05 and trends were reported as 0.05 &#x0003c; &#x003b1; &#x0003c; 0.10.</p></sec></sec><sec sec-type="results" id="S14"><title>Results</title><p id="P15">The raw data for fitness, body composition, fasting glucose and insulin have been published previously (<xref rid="R19" ref-type="bibr">19</xref>). However, given the obvious relevance of those data to risk for CVD they are summarized here for clarity.</p><sec id="S15"><title>Cardiorespiratory fitness and strength</title><p id="P16">Exercise training plus metformin (EM) and exercise training plus placebo (EP) increased VO<sub>2</sub>peak by 10&#x02013;20% compared to baseline and strength by approximately 15% compared to baseline (<xref rid="R19" ref-type="bibr">19</xref>).</p></sec><sec id="S16"><title>Weight change, body composition &#x00026; food intake</title><p id="P17">Metformin (M) and EM, but not EP, decreased body weight more than P (p &#x0003c; 0.05; <xref ref-type="fig" rid="F1">Figure 1a</xref>). EM and EP also lowered percent body fat (P = &#x02212;0.8 &#x000b1; 0.6%; M = 0.1 &#x000b1; 0.5%; EP = &#x02212;2.2 &#x000b1; 0.8%; EM = &#x02212;1.5 &#x000b1; 0.7%) and central body fat (P = &#x02212;0.6 &#x000b1; 0.1%; M = &#x02212;0.1 &#x000b1; 0.6%; EP = &#x02212;1.4 &#x000b1; 0.5%; EM = &#x02212;1.9 &#x000b1; 0.6%) by similar amounts. Waist circumference was 2&#x02013;3% lower after all 3 treatments compared to baseline (time effect: p &#x0003c; 0.01; <xref ref-type="fig" rid="F2">Figure 1b</xref>), but was not different across groups. Caloric intake was decreased by approximately 15% from baseline for M (2107.3 &#x000b1; 103.2 vs. 1819.8kcal; p &#x0003c; 0.05) and EM (2251.0 &#x000b1; 135.7 vs. 1777.3 &#x000b1; 130.2kcal; p &#x0003c; 0.05). Both EP (2292.0 &#x000b1; 177.8 vs. 2149.2 &#x000b1; 138.1kcal; p = 0.57) and P (1923.22 &#x000b1; 135.6 vs. 1861.3 &#x000b1;144.5; p = 0.69) had no effect on intake.</p></sec><sec id="S17"><title>Fasting plasma glucose and insulin</title><p id="P18">Exercise training and/or metformin had no effect on fasting glucose concentrations (P = &#x02212;0.1 &#x000b1; 0.2mM; M = &#x02212;0.2 &#x000b1; 0.3mM; EP = 0.0 &#x000b1; 0.3mM; EM = &#x02212;0.4 &#x000b1; 0.2mM). All 3 treatments lowered fasting insulin concentrations (P = 1.5 &#x000b1; 2.3uU/ml; M = &#x02212;5.2 &#x000b1; 1.9 uU/ml; EP = &#x02212;1.7 &#x000b1; 0.7uU/ml; EM = &#x02212;2.9 &#x000b1; 1.5uU/ml), but there were no group differences.</p></sec><sec id="S18"><title>Blood pressure</title><p id="P19">Compared to baseline, SBP and DBP increased with placebo (P; p &#x0003c; 0.05). M and EP lowered SBP (p &#x0003c; 0.01), but all 3 treatments lowered DBP compared to P (p &#x0003c; 0.05; <xref ref-type="table" rid="T2">Table 2</xref>). Both M and EP decreased MAP compared to P (p &#x0003c; 0.05; <xref ref-type="table" rid="T2">Table 2</xref>) but there was no change after EM.</p></sec><sec id="S19"><title>High-sensitivity-C-reactive protein (hs-CRP)</title><p id="P20">EP and M, but not EM, lowered CRP by approximately 20% compared to P (EP: p &#x0003c; 0.05 and M: trend p = 0.06; Table 4).</p></sec><sec id="S20"><title>Triacylglycerol (TAG) and Cholesterol</title><p id="P21">Compared to baseline, exercise and/or metformin lowered TAG by approximately 13% (time effect: p &#x0003c; 0.05; <xref ref-type="table" rid="T3">Table 3</xref>), but there were no group differences. All 3 treatments raised HDL cholesterol concentrations by 8&#x02013;13% compared to P (M or EP; p &#x0003c; 0.05 and EM; trend p = 0.06; <xref ref-type="table" rid="T3">Table 3</xref>). Each treatment also decreased the cardiac risk ratio (p &#x0003c; 0.05; <xref ref-type="table" rid="T3">Table 3</xref>).</p></sec><sec id="S21"><title>Metabolic syndrome severity and prevalence</title><p id="P22">Exercise training and/or metformin reduced the metabolic syndrome Z-score (i.e. severity) compared to baseline (EP; trend p = 0.07 and EM or M; p &#x0003c; 0.05; <xref ref-type="fig" rid="F3">Figure 2a</xref>). Although each treatment reversed metabolic syndrome prevalence (M = 6 to 1; EP = 7 to 4; EM 6 to 3; p &#x0003c; 0.05; <xref ref-type="fig" rid="F4">Figure 2b</xref>), only EP and M reduced ATP III criteria (p &#x0003c; 0.05) compared to baseline (<xref ref-type="fig" rid="F5">Figure 2c</xref>).</p></sec><sec id="S22"><title>Correlation Analysis</title><p id="P23">Increased cardiorespiratory fitness was significantly correlated with lower fasting glucose concentrations (r = &#x02212;0.38; p &#x0003c; 0.05) but not with any other CVD risk factor. Weight loss was correlated with lower fasting insulin concentrations (r = 0.40; p &#x0003c; 0.05), caloric intake (r = 0.46; p &#x0003c; 0.05) and waist circumference (r = 0.60; p &#x0003c; 0.05). Reductions in TAG concentrations were correlated with increased insulin sensitivity (r = &#x02212;0.60; p &#x0003c; 0.05). Lower hs-CRP concentrations were correlated with decreased systolic blood pressure (r = 0.46; p &#x0003c; 0.05).</p></sec></sec><sec sec-type="discussion" id="S23"><title>Discussion</title><p id="P24">Metformin is not only used to treat type 2 diabetes, but it is also suggested to reduce cardiovascular disease (CVD) risk factors in adults with impaired glucose tolerance (IGT) (<xref rid="R23" ref-type="bibr">23</xref>). Previous work suggested that exercise with metformin reduced CVD risk factors more than the respective treatments alone (<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>), however, we observed no additive effect of combining exercise with metformin to reduce CVD risk factors IGT men and women. There are several possible differences between studies that may explain this. First, previous work did not systematically compare the combined treatment to either exercise (<xref rid="R17" ref-type="bibr">17</xref>) or metformin alone (<xref rid="R18" ref-type="bibr">18</xref>), thereby limiting the ability to know the effectiveness of the combined treatment on CVD risk factors. Second, recommendations to increased physical activity were not structured or supervised (<xref rid="R18" ref-type="bibr">18</xref>). Third, differences between HIV infected patients and IGT pathophysiology (<xref rid="R17" ref-type="bibr">17</xref>) complicate comparing previous work to ours. Last, dietary manipulations (i.e. low-fat diet) confound the ability to identify the independent effect of exercise with metformin on CVD risk factors (<xref rid="R18" ref-type="bibr">18</xref>). Consistent with our previous work (<xref rid="R19" ref-type="bibr">19</xref>), the current findings suggest that metformin may blunt some of the beneficial effects of training to lower systolic blood pressure, hs-CRP and metabolic syndrome criteria.</p><p id="P25">Weight loss (i.e. fat loss) is associated with lower CVD risk. Although exercise training with ad libitum food intake has mixed effects on weight loss (<xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R25" ref-type="bibr">25</xref>), combining it with metformin has been shown to cause greater weight loss (<xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>). We found that combining metformin with exercise reduced body weight by approximately 4kg more than exercise alone, however, this was not different than metformin alone. Neither metformin, alone or with exercise, affected CVD risk factors (i.e. blood lipids, blood pressure, hs-CRP) more than exercise alone. Comparable reductions in central body fat between the exercise groups may explain the similar effects of exercise at reducing blood lipids (e.g. TAG and TC) (<xref rid="R19" ref-type="bibr">19</xref>). However, metformin decreased blood lipids equivalently to either exercise group without a change in central fat (measured by DEXA and waist circumference). Although we report reductions in waist circumferences with metformin in this study, more direct measures of central fat (e.g. MRI or CT scan) would be needed to confirm a true change in visceral fat., Despite no strong correlation between weight loss or waist circumference and CVD risk factors, we cannot rule out the possibility that fat loss explains at least some of the metformin group outcomes. In either case, these results suggest that each treatment has distinctive mechanisms for opposing CVD development.</p><p id="P26">Blood pressure is often lowered after exercise training (<xref rid="R11" ref-type="bibr">11</xref>), but the effects of metformin are less consistent (<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R31" ref-type="bibr">31</xref>). We found that metformin yielded little added benefit to the effects of exercise training on lowering blood pressure and this outcome is consistent with other work (<xref rid="R18" ref-type="bibr">18</xref>). Our data suggest that the interaction of metformin with exercise training blunts reductions in systolic blood pressure, and these results may be related to changes in cardiorespiratory fitness. Although there were no statistical differences in VO<sub>2</sub>peak between the exercise groups, the attenuated rise in VO<sub>2</sub>peak (EM = 10% vs. EP = 20%) is worth considering since it is consistent with our previous work in healthy adults (<xref rid="R32" ref-type="bibr">32</xref>). The smaller rise in VO<sub>2</sub>peak is likely a result of either alterations in mitochondrial adaptations or vascular blood flow. Although we did not directly measure endothelial function, we found that exercise training or metformin alone, but not the combined treatment, reduced the vascular inflammatory marker hs-CRP by approximately 20% compared to placebo. We observed a significant correlation between the change in hs-CRP and systolic blood pressure, suggesting that reduced systolic blood pressure may be related to decreased vascular inflammation. Interestingly, metformin alone reduced both systolic blood pressure and hs-CRP, but had no effect on VO<sub>2</sub>peak compared to placebo. This result strengthens the hypothesis that there is a unique interaction between metformin and exercise on the aforementioned outcomes that could have opposing effects on cardiovascular health. From this study, we cannot determine the mechanism by which the combined treatment blunted reductions in systolic blood pressure or serum hs-CRP concentrations, but it may be related to the interaction between nitric oxide synthesis and AMPK activation (<xref rid="R33" ref-type="bibr">33</xref>, <xref rid="R34" ref-type="bibr">34</xref>). Exercise combined with metformin was previously shown to blunt AMPK activation in skeletal muscle (<xref rid="R35" ref-type="bibr">35</xref>). Since AMPK activation is important for nitric oxide production, it is possible that the combined treatment blunted nitric oxide production and affected systolic blood pressure and hs-CRP concentrations.</p><p id="P27">Although combining metformin with lifestyle modification lowered TAG concentrations more than lifestyle modification alone in overweight insulin resistant adolescents (<xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R28" ref-type="bibr">28</xref>), there was no additive effect in IGT adults (<xref rid="R18" ref-type="bibr">18</xref>). Consistent with Andreadis et al (<xref rid="R18" ref-type="bibr">18</xref>), we found that exercise training and/or metformin had similar effects at lowering TAG concentrations, despite exercise increasing VO<sub>2</sub>peak and reducing central body fat. The decline in TAG concentrations across treatments was associated with increased insulin sensitivity (r = &#x02212;0.60; p &#x0003c; 0.05). Although we cannot prove causality or directionality from this correlation, a possibility is that reductions in circulating TAG lead to improved peripheral glucose uptake (<xref rid="R36" ref-type="bibr">36</xref>). Fasting non-esterified fatty acids (NEFA) concentrations were elevated after exercise training with metformin, which could potentially explain the blunted rise in insulin sensitivity (<xref rid="R19" ref-type="bibr">19</xref>). The incongruent finding between lower TAG and higher NEFA concentrations with exercise plus metformin may relate to decreased NEFA uptake in skeletal muscle and liver (<xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R38" ref-type="bibr">38</xref>) or increased lipolytic activity (<xref rid="R39" ref-type="bibr">39</xref>). We are not able to discern which of the mechanisms account for elevated NEFA concentrations, but our results support the beneficial effects of exercise to lower TAG and increase insulin sensitivity (<xref rid="R40" ref-type="bibr">40</xref>). Whether exercise and/or metformin treatments have a direct impact on reducing CVD incidence in individuals with IGT remains to be seen.</p><p id="P28">Approximately 50% of individuals with IGT have metabolic syndrome (<xref rid="R3" ref-type="bibr">3</xref>). Lifestyle modification or metformin decrease metabolic syndrome prevalence (<xref rid="R3" ref-type="bibr">3</xref>), and the combined treatment may have additive effects (<xref rid="R18" ref-type="bibr">18</xref>). In this study, we showed that structured exercise training and/or metformin had similar effects on reducing metabolic syndrome severity (i.e. Z-score; <xref ref-type="fig" rid="F3">Figure 2a</xref>). The initial ATP III score was lower in the exercise with metformin group, compared with either treatment alone. The lower baseline may have made it more difficult to detect a significant improvement from baseline, and, only exercise training or metformin alone reduced the number of subjects meeting ATP III criteria (<xref ref-type="fig" rid="F5">Figure 2c</xref>). In addition, although not statistically different, metformin decreased metabolic syndrome prevalence more than the combined treatment (<xref ref-type="fig" rid="F4">Figure 2b</xref>). Since the combined treatment did not lower systolic blood pressure, an ATP III criteria factor, our findings suggest that the interaction of metformin and exercise may oppose the reversal of metabolic syndrome in IGT adults compared to metformin alone. We recognize that further work is needed given the modest sample size in this study and our inability to compare treatment groups to placebo because only 2 subjects in that group had metabolic syndrome. However, the novel observation from this study is that combining exercise with metformin may have opposing effects on cardiovascular health, which could be clinically significant (<xref rid="R16" ref-type="bibr">16</xref>).</p><p id="P29">In conclusion, we observed that combining metformin with structured exercise training did not have additive effects on any CVD risk factor measured in this group of IGT adults. Metformin may blunt some of the effects of exercise training on lowering systolic blood pressure and hs-C-reactive protein and consequently contribute to preventing a decrease in the number of metabolic syndrome risk factors. If our results are reproduced and generalizable to men and women with IGT then the clinical utility of recommending the combination of exercise and metformin for people with IGT may need to be re-evaluated. Despite metformin alone reducing CVD risk factors comparably to exercise alone, the improvements in cardiorespiratory fitness after exercise is one of the best predictors of CVD and early mortality. As a result, our findings highlight the overall positive effects of exercise on lowering CVD risk in adults with IGT.</p></sec></body><back><ack id="S24"><title>Acknowledgments</title><p>S.K.M, S.R.C, and B.B. contributed to the study design and data collection. S.K.M was primarily responsible for data analysis and statistical integrity. J.N. contributed to data entry and data analysis. S.C. was solely responsible for food data analysis. S.K.M, S.R.C, and B.B. wrote the manuscript and J.N and S.C. reviewed/edited the manuscript. The authors would like to thank Kirsten Granados, Richard Viskochil, and Robert Gerber for technical assistance and helpful discussion. B.B. receives consulting fees from Pfizer Global Inc. We thank all the dedicated participants and research assistants for assistance on this project. This research was supported by NIH 5 R56 DK081038 Grant.</p></ack><ref-list><title>REFERENCES</title><ref id="R1"><label>(1)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blake</surname><given-names>D</given-names></name><name><surname>Meigs</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>D</given-names></name><name><surname>Najjar</surname><given-names>S</given-names></name><name><surname>Andres</surname><given-names>R</given-names></name><name><surname>Nathan</surname><given-names>D</given-names></name></person-group><article-title>Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><issue>8</issue><fpage>2095</fpage><lpage>2100</lpage><pub-id pub-id-type="pmid">15277391</pub-id></element-citation></ref><ref id="R2"><label>(2)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Festa</surname><given-names>A</given-names></name><name><surname>D'Agostino</surname><given-names>R</given-names></name><name><surname>Howard</surname><given-names>G</given-names></name><name><surname>Mykknen</surname><given-names>L</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Haffner</surname><given-names>SM</given-names></name></person-group><article-title>Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)</article-title><source>Circulation</source><year>2000</year><volume>102</volume><issue>1</issue><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">10880413</pub-id></element-citation></ref><ref id="R3"><label>(3)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orchard</surname><given-names>TJ</given-names></name><name><surname>Temprosa</surname><given-names>M</given-names></name><name><surname>Goldberg</surname><given-names>R</given-names></name><name><surname>Haffner</surname><given-names>S</given-names></name><name><surname>Ratner</surname><given-names>R</given-names></name><name><surname>Marcovina</surname><given-names>S</given-names></name><etal/></person-group><article-title>The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial</article-title><source>Ann Intern Med</source><year>2005</year><volume>142</volume><issue>8</issue><fpage>611</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">15838067</pub-id></element-citation></ref><ref id="R4"><label>(4)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haffner</surname><given-names>S</given-names></name></person-group><article-title>Insulin resistance, inflammation, and the prediabetic state</article-title><source>Am J Cardiol</source><year>2003</year><volume>92</volume><issue>4A</issue><fpage>18J</fpage><lpage>26J</lpage></element-citation></ref><ref id="R5"><label>(5)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unwin</surname><given-names>N</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name><name><surname>Zimmet</surname><given-names>P</given-names></name><name><surname>Alberti</surname><given-names>KGMM</given-names></name></person-group><article-title>Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention</article-title><source>Diabetic Med</source><year>2002</year><volume>19</volume><issue>9</issue><fpage>708</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">12207806</pub-id></element-citation></ref><ref id="R6"><label>(6)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houmard</surname><given-names>JA</given-names></name><name><surname>Tanner</surname><given-names>CJ</given-names></name><name><surname>Slentz</surname><given-names>CA</given-names></name><name><surname>Duscha</surname><given-names>BD</given-names></name><name><surname>McCartney</surname><given-names>JS</given-names></name><name><surname>Kraus</surname><given-names>WE</given-names></name></person-group><article-title>Effect of the volume and intensity of exercise training on insulin sensitivity</article-title><source>J Appl Physiol</source><year>2004</year><volume>96</volume><issue>1</issue><fpage>101</fpage><pub-id pub-id-type="pmid">12972442</pub-id></element-citation></ref><ref id="R7"><label>(7)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dela</surname><given-names>F</given-names></name><name><surname>Larsen</surname><given-names>JJ</given-names></name><name><surname>Mikines</surname><given-names>KJ</given-names></name><name><surname>Ploug</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>LN</given-names></name><name><surname>Galbo</surname><given-names>H</given-names></name></person-group><article-title>Insulin-stimulated muscle glucose clearance in patients with NIDDM. Effects of one-legged physical training</article-title><source>Diabetes</source><year>1995</year><volume>44</volume><issue>9</issue><fpage>1010</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">7657022</pub-id></element-citation></ref><ref id="R8"><label>(8)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holten</surname><given-names>MK</given-names></name><name><surname>Zacho</surname><given-names>M</given-names></name><name><surname>Gaster</surname><given-names>M</given-names></name><name><surname>Juel</surname><given-names>C</given-names></name><name><surname>Wojtaszewski</surname><given-names>JFP</given-names></name><name><surname>Dela</surname><given-names>F</given-names></name></person-group><article-title>Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><issue>2</issue><fpage>294</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">14747278</pub-id></element-citation></ref><ref id="R9"><label>(9)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durstine</surname><given-names>JL</given-names></name><name><surname>Grandjean</surname><given-names>P</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>P</given-names></name></person-group><article-title>Lipids, lipoproteins, and exercise</article-title><source>J Cardiopulm Rehabil</source><year>2002</year><volume>22</volume><issue>6</issue><fpage>385</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">12464825</pub-id></element-citation></ref><ref id="R10"><label>(10)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herder</surname><given-names>C</given-names></name><name><surname>Peltonen</surname><given-names>M</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Stfels</surname><given-names>K</given-names></name><name><surname>Lindstrm</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study</article-title><source>Diabetologia</source><year>2009</year><volume>52</volume><issue>3</issue><fpage>433</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">19130041</pub-id></element-citation></ref><ref id="R11"><label>(11)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacon</surname><given-names>S</given-names></name><name><surname>Sherwood</surname><given-names>A</given-names></name><name><surname>Hinderliter</surname><given-names>A</given-names></name><name><surname>Blumenthal</surname><given-names>J</given-names></name></person-group><article-title>Effects of exercise, diet and weight loss on high blood pressure</article-title><source>Sports Med</source><year>2004</year><volume>34</volume><issue>5</issue><fpage>307</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">15107009</pub-id></element-citation></ref><ref id="R12"><label>(12)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musi</surname><given-names>N</given-names></name><name><surname>Hirshman</surname><given-names>MF</given-names></name><name><surname>Nygren</surname><given-names>J</given-names></name><name><surname>Svanfeldt</surname><given-names>M</given-names></name><name><surname>Bavenholm</surname><given-names>P</given-names></name><name><surname>Rooyackers</surname><given-names>O</given-names></name><etal/></person-group><article-title>Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><issue>7</issue><fpage>2074</fpage><lpage>2081</lpage><pub-id pub-id-type="pmid">12086935</pub-id></element-citation></ref><ref id="R13"><label>(13)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehtovirta</surname><given-names>M</given-names></name><name><surname>Fors&#x000e9;n</surname><given-names>B</given-names></name><name><surname>Gullstr&#x000f6;m</surname><given-names>M</given-names></name><name><surname>H&#x000e4;ggblom</surname><given-names>M</given-names></name><name><surname>Eriksson</surname><given-names>JG</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Metabolic effects of metformin in patients with impaired glucose tolerance</article-title><source>Diabet Med</source><year>2001</year><volume>18</volume><issue>7</issue><fpage>578</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">11553189</pub-id></element-citation></ref><ref id="R14"><label>(14)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusi</surname><given-names>K</given-names></name><name><surname>Consoli</surname><given-names>A</given-names></name><name><surname>DeFronzo</surname><given-names>RA</given-names></name></person-group><article-title>Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus</article-title><source>J Clin Endocrinol Metab</source><year>1996</year><volume>81</volume><issue>11</issue><fpage>4059</fpage><lpage>4067</lpage><pub-id pub-id-type="pmid">8923861</pub-id></element-citation></ref><ref id="R15"><label>(15)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Barzilai</surname><given-names>N</given-names></name><name><surname>Simonson</surname><given-names>DC</given-names></name></person-group><article-title>Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects</article-title><source>J Clin Endocrinol Metab</source><year>1991</year><volume>73</volume><issue>6</issue><fpage>1294</fpage><lpage>1301</lpage><pub-id pub-id-type="pmid">1955512</pub-id></element-citation></ref><ref id="R16"><label>(16)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>M</given-names></name><name><surname>Herrick</surname><given-names>K</given-names></name><name><surname>Ziemer</surname><given-names>D</given-names></name><name><surname>Vaccarino</surname><given-names>V</given-names></name><name><surname>Weintraub</surname><given-names>W</given-names></name><name><surname>Narayan</surname><given-names>KMV</given-names></name><etal/></person-group><article-title>Many Americans have pre-diabetes and should be considered for metformin therapy</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><issue>1</issue><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">19808929</pub-id></element-citation></ref><ref id="R17"><label>(17)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driscoll</surname><given-names>SD</given-names></name><name><surname>Meininger</surname><given-names>GE</given-names></name><name><surname>Lareau</surname><given-names>MT</given-names></name><name><surname>Dolan</surname><given-names>SE</given-names></name><name><surname>Killilea</surname><given-names>KM</given-names></name><name><surname>Hadigan</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients</article-title><source>AIDS</source><year>2004</year><volume>18</volume><issue>3</issue><fpage>465</fpage><pub-id pub-id-type="pmid">15090799</pub-id></element-citation></ref><ref id="R18"><label>(18)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreadis</surname><given-names>EA</given-names></name><name><surname>Katsanou</surname><given-names>PM</given-names></name><name><surname>Georgiopoulos</surname><given-names>DX</given-names></name><name><surname>Tsourous</surname><given-names>GI</given-names></name><name><surname>Yfanti</surname><given-names>GK</given-names></name><name><surname>Gouveri</surname><given-names>ET</given-names></name><etal/></person-group><article-title>The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study</article-title><source>Exp Clin Endocrinol Diabetes</source><year>2009</year><volume>117</volume><issue>4</issue><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">19053032</pub-id></element-citation></ref><ref id="R19"><label>(19)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malin</surname><given-names>S</given-names></name><name><surname>Gerber</surname><given-names>R</given-names></name><name><surname>Chipkin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Independent and Combined Effects of Exercise Training and Metformin on Insulin Sensitivity in Individuals With Prediabetes</article-title><source>Diabetes Care</source><year>2011</year><volume>35</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage></element-citation></ref><ref id="R20"><label>(20)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reaven</surname><given-names>GM</given-names></name></person-group><article-title>Pathophysiology of insulin resistance in human disease</article-title><source>Physiol Rev</source><year>1995</year><volume>1995</volume><fpage>473</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">7624391</pub-id></element-citation></ref><ref id="R21"><label>(21)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Slentz</surname><given-names>C</given-names></name><name><surname>Houmard</surname><given-names>J</given-names></name><name><surname>Samsa</surname><given-names>G</given-names></name><name><surname>Duscha</surname><given-names>B</given-names></name><name><surname>Aiken</surname><given-names>L</given-names></name><etal/></person-group><article-title>Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise)</article-title><source>Am J Cardiol</source><year>2007</year><volume>100</volume><issue>12</issue><fpage>1759</fpage><pub-id pub-id-type="pmid">18082522</pub-id></element-citation></ref><ref id="R22"><label>(22)</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fleiss</surname><given-names>JL</given-names></name></person-group><source>Statistical methods for rates and proportions</source><year>1981</year><fpage>114</fpage><publisher-name>John Wiley</publisher-name><publisher-loc>New York</publisher-loc></element-citation></ref><ref id="R23"><label>(23)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>C</given-names></name></person-group><article-title>Metformin: effects on micro and macrovascular complications in type 2 diabetes</article-title><source>Cardiovascular drugs and therapy</source><year>2008</year><volume>22</volume><issue>3</issue><fpage>215</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">18288595</pub-id></element-citation></ref><ref id="R24"><label>(24)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Church</surname><given-names>T</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Earnest</surname><given-names>C</given-names></name><name><surname>Mikus</surname><given-names>C</given-names></name><name><surname>Blair</surname><given-names>S</given-names></name></person-group><article-title>Changes in weight, waist circumference and compensatory responses with different doses of exercise among sedentary, overweight postmenopausal women</article-title><source>PloS one</source><year>2009</year><volume>4</volume><issue>2</issue><fpage>e4515</fpage><lpage>e4515</lpage><pub-id pub-id-type="pmid">19223984</pub-id></element-citation></ref><ref id="R25"><label>(25)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>J</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name><name><surname>Jacobsen</surname><given-names>D</given-names></name><name><surname>Potteiger</surname><given-names>J</given-names></name><name><surname>Sullivan</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effects of a 16-month randomized controlled exercise trial on body weight and composition in young, overweight men and women: the Midwest Exercise Trial</article-title><source>Arch Intern Med</source><year>2003</year><volume>163</volume><issue>11</issue><fpage>1343</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">12796071</pub-id></element-citation></ref><ref id="R26"><label>(26)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarson</surname><given-names>C</given-names></name><name><surname>Mahmud</surname><given-names>F</given-names></name><name><surname>Baker</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>H</given-names></name><name><surname>McKay</surname><given-names>W</given-names></name><name><surname>Schauteet</surname><given-names>V</given-names></name><etal/></person-group><article-title>Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance</article-title><source>Endocrine</source><year>2009</year><volume>36</volume><issue>1</issue><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">19387874</pub-id></element-citation></ref><ref id="R27"><label>(27)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love-Osborne</surname><given-names>K</given-names></name><name><surname>Sheeder</surname><given-names>J</given-names></name><name><surname>Zeitler</surname><given-names>P</given-names></name></person-group><article-title>Addition of metformin to a lifestyle modification program in adolescents with insulin resistance</article-title><source>J Pediatr</source><year>2008</year><volume>152</volume><issue>6</issue><fpage>817</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">18492523</pub-id></element-citation></ref><ref id="R28"><label>(28)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atabek</surname><given-names>M</given-names></name><name><surname>Pirgon</surname><given-names>O</given-names></name></person-group><article-title>Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial</article-title><source>J Pediatr Endocrinol Metab</source><year>2008</year><volume>21</volume><issue>4</issue><fpage>339</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">18556965</pub-id></element-citation></ref><ref id="R29"><label>(29)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landin</surname><given-names>K</given-names></name><name><surname>Tengborn</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>U</given-names></name></person-group><article-title>Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors</article-title><source>J Intern Med</source><year>1991</year><volume>229</volume><issue>2</issue><fpage>181</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">1900072</pub-id></element-citation></ref><ref id="R30"><label>(30)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giugliano</surname><given-names>D</given-names></name><name><surname>De Rosa</surname><given-names>N</given-names></name><name><surname>Di Maro</surname><given-names>G</given-names></name><name><surname>Marfella</surname><given-names>R</given-names></name><name><surname>Acampora</surname><given-names>R</given-names></name><name><surname>Buoninconti</surname><given-names>R</given-names></name><etal/></person-group><article-title>Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women</article-title><source>Diabetes Care</source><year>1993</year><volume>16</volume><issue>10</issue><fpage>1387</fpage><lpage>1390</lpage><pub-id pub-id-type="pmid">8269798</pub-id></element-citation></ref><ref id="R31"><label>(31)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorella</surname><given-names>M</given-names></name><name><surname>Giusto</surname><given-names>M</given-names></name><name><surname>Da Tos</surname><given-names>V</given-names></name><name><surname>Campagnolo</surname><given-names>M</given-names></name><name><surname>Palatini</surname><given-names>P</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance</article-title><source>J Clin Endocrinol Metab</source><year>1996</year><volume>81</volume><issue>4</issue><fpage>1568</fpage><lpage>1574</lpage><pub-id pub-id-type="pmid">8636369</pub-id></element-citation></ref><ref id="R32"><label>(32)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>B</given-names></name><name><surname>Eze</surname><given-names>P</given-names></name><name><surname>Stephens</surname><given-names>BR</given-names></name><name><surname>Hagobian</surname><given-names>TA</given-names></name><name><surname>Sharoff</surname><given-names>CG</given-names></name><name><surname>Chipkin</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Impact of metformin on peak aerobic capacity</article-title><source>Appl Physiol Nutr Metab</source><year>2008</year><volume>33</volume><issue>1</issue><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">18347654</pub-id></element-citation></ref><ref id="R33"><label>(33)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Dumont</surname><given-names>A</given-names></name><name><surname>Fedak</surname><given-names>PWM</given-names></name><name><surname>Badiwala</surname><given-names>M</given-names></name><etal/></person-group><article-title>A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis</article-title><source>Circulation</source><year>2002</year><volume>106</volume><issue>8</issue><fpage>913</fpage><lpage>919</lpage><pub-id pub-id-type="pmid">12186793</pub-id></element-citation></ref><ref id="R34"><label>(34)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lira</surname><given-names>V</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Lira</surname><given-names>A</given-names></name><name><surname>Kavazis</surname><given-names>A</given-names></name><name><surname>Soltow</surname><given-names>Q</given-names></name><name><surname>Zeanah</surname><given-names>E</given-names></name><etal/></person-group><article-title>Nitric oxide and AMPK cooperatively regulate PGC-1 in skeletal muscle cells</article-title><source>J Physiol (Lond )</source><year>2010</year><volume>588</volume><issue>Pt 18</issue><fpage>3551</fpage><pub-id pub-id-type="pmid">20643772</pub-id></element-citation></ref><ref id="R35"><label>(35)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharoff</surname><given-names>C</given-names></name><name><surname>Hagobian</surname><given-names>T</given-names></name><name><surname>Malin</surname><given-names>S</given-names></name><name><surname>Chipkin</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Hirshman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Combining short-term metformin treatment and one bout of exercise does not increase insulin action in insulin resistant individuals</article-title><source>Am J Physiol Endocrinol Metab</source><year>2010</year><volume>298</volume><issue>4</issue><fpage>E815</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">20071560</pub-id></element-citation></ref><ref id="R36"><label>(36)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>W</given-names></name><name><surname>Slentz</surname><given-names>C</given-names></name></person-group><article-title>Exercise training, lipid regulation, and insulin action: a tangled web of cause and effect</article-title><source>Obesity</source><year>2009</year><volume>17</volume><issue>Suppl 3</issue><fpage>S21</fpage><lpage>S26</lpage><pub-id pub-id-type="pmid">19927141</pub-id></element-citation></ref><ref id="R37"><label>(37)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>AC</given-names></name><name><surname>Mullen</surname><given-names>KL</given-names></name><name><surname>Junkin</surname><given-names>KA</given-names></name><name><surname>Nickerson</surname><given-names>J</given-names></name><name><surname>Chabowski</surname><given-names>A</given-names></name><name><surname>Bonen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia</article-title><source>Am J Physiol Endocrinol Metab</source><year>2007</year><volume>293</volume><issue>1</issue><fpage>E172</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">17374701</pub-id></element-citation></ref><ref id="R38"><label>(38)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iozzo</surname><given-names>P</given-names></name><name><surname>Hallsten</surname><given-names>K</given-names></name><name><surname>Oikonen</surname><given-names>V</given-names></name><name><surname>Virtanen</surname><given-names>K</given-names></name><name><surname>Parkkola</surname><given-names>R</given-names></name><name><surname>Kemppainen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><issue>7</issue><fpage>2069</fpage><lpage>2074</lpage><pub-id pub-id-type="pmid">12832315</pub-id></element-citation></ref><ref id="R39"><label>(39)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>H</given-names></name><name><surname>Hirshman</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Manabe</surname><given-names>Y</given-names></name><name><surname>Balschi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Adrenaline is a critical mediator of acute exercise-induced AMP-activated protein kinase activation in adipocytes</article-title><source>Biochem J</source><year>2007</year><volume>403</volume><issue>3</issue><fpage>473</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">17253964</pub-id></element-citation></ref><ref id="R40"><label>(40)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slentz</surname><given-names>C</given-names></name><name><surname>Houmard</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Bateman</surname><given-names>L</given-names></name><name><surname>Tanner</surname><given-names>C</given-names></name><name><surname>McCartney</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inactivity, exercise training and detraining, and plasma lipoproteins. STRRIDE: a randomized, controlled study of exercise intensity and amount</article-title><source>J Appl Physiol</source><year>2007</year><volume>103</volume><issue>2</issue><fpage>432</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">17395756</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1a</label><caption><p>Change in body weight over the 12 week protocol. ^Significant effect of M and EM compared to P (p &#x0003c; 0.05). Significant effect of M(*) and EM(&#x02021;) compared to baseline (p &#x0003c; 0.05). Data are mean &#x000b1; standard error of the mean.</p></caption><graphic xlink:href="nihms-378375-f0001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 1b</label><caption><p>Change in waist circumference over the 12 week intervention. *Significant effect of time (p &#x0003c; 0.05). Data are mean &#x000b1; standard error of the mean.</p></caption><graphic xlink:href="nihms-378375-f0002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 2a</label><caption><p>Metabolic syndrome severity before and after the 12 week intervention. *Pre to post was statistically different by paired t-test; p &#x0003c; 0.05. <sup>$</sup>p = 0.07. Data are mean &#x000b1; standard error of the mean.</p></caption><graphic xlink:href="nihms-378375-f0003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 2b</label><caption><p>Metabolic syndrome prevalence before and after the 12 week intervention. Prevalence refers to the fraction of individuals with metabolic syndrome pre and post. *Pre to post was statistically different by McNemar; p &#x0003c; 0.05. Data are frequency.</p></caption><graphic xlink:href="nihms-378375-f0004"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 2c</label><caption><p>ATP III score before and after the 12 week intervention. *Pre to post was statistically different by paired t-test; p &#x0003c; 0.05. Data are mean &#x000b1; standard error of the mean.</p></caption><graphic xlink:href="nihms-378375-f0005"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Subject Characteristics.</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">P</th><th align="center" valign="middle" rowspan="1" colspan="1">M</th><th align="center" valign="middle" rowspan="1" colspan="1">EP</th><th align="center" valign="middle" rowspan="1" colspan="1">EM</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex</td><td align="center" valign="middle" rowspan="1" colspan="1">6F/2M</td><td align="center" valign="middle" rowspan="1" colspan="1">4F/4M</td><td align="center" valign="middle" rowspan="1" colspan="1">5F/3M</td><td align="center" valign="middle" rowspan="1" colspan="1">5F/3M</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (year)</td><td align="center" valign="middle" rowspan="1" colspan="1">49.8 &#x000b1; 10.9</td><td align="center" valign="middle" rowspan="1" colspan="1">45.0 &#x000b1; 7.5</td><td align="center" valign="middle" rowspan="1" colspan="1">45.4 &#x000b1; 8.0</td><td align="center" valign="middle" rowspan="1" colspan="1">49.1 &#x000b1; 6.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">34.0 &#x000b1; 6.3</td><td align="center" valign="middle" rowspan="1" colspan="1">33.9 &#x000b1; 5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">33.5 &#x000b1; 4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">31.2 &#x000b1; 5.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Body weight (kg)</td><td align="center" valign="middle" rowspan="1" colspan="1">93.5 &#x000b1; 6.0</td><td align="center" valign="middle" rowspan="1" colspan="1">101.5 &#x000b1; 5.8</td><td align="center" valign="middle" rowspan="1" colspan="1">95.5 &#x000b1; 5.1</td><td align="center" valign="middle" rowspan="1" colspan="1">94.1 &#x000b1; 6.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VO<sub>2</sub> peak (ml/kg-ffm/min)</td><td align="center" valign="middle" rowspan="1" colspan="1">41.2 &#x000b1; 8.2</td><td align="center" valign="middle" rowspan="1" colspan="1">43.4 &#x000b1; 10.3</td><td align="center" valign="middle" rowspan="1" colspan="1">45.7 &#x000b1; 9.4</td><td align="center" valign="middle" rowspan="1" colspan="1">48.2 &#x000b1; 4.9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Fasting Glucose (mM)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.79 &#x000b1; 0.57</td><td align="center" valign="middle" rowspan="1" colspan="1">5.58 &#x000b1; 0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">5.42 &#x000b1; 0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">5.46 &#x000b1; 0.80</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2-hour Glucose (mM)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.38 &#x000b1; 1.33</td><td align="center" valign="middle" rowspan="1" colspan="1">9.28 &#x000b1; 1.53</td><td align="center" valign="middle" rowspan="1" colspan="1">10.23 &#x000b1; 1.02</td><td align="center" valign="middle" rowspan="1" colspan="1">9.46 &#x000b1; 1.70</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Steps per day</td><td align="center" valign="middle" rowspan="1" colspan="1">4983.9 &#x000b1; 2104.9</td><td align="center" valign="middle" rowspan="1" colspan="1">5028.1 &#x000b1; 2047.7</td><td align="center" valign="middle" rowspan="1" colspan="1">5871.7 &#x000b1; 1912.8</td><td align="center" valign="middle" rowspan="1" colspan="1">6444.6 &#x000b1; 1529.9</td></tr></tbody></table><table-wrap-foot><p>No significant differences were observed between conditions.</p><p>Data are mean &#x000b1; standard deviation.</p></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="landscape"><label>Table 2</label><caption><p>Effect of exercise and/or metformin on blood pressure.</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Condition</th><th align="left" valign="top" rowspan="1" colspan="1">Test</th><th align="center" valign="top" rowspan="1" colspan="1">P</th><th align="center" valign="top" rowspan="1" colspan="1">M</th><th align="center" valign="top" rowspan="1" colspan="1">EP</th><th align="center" valign="top" rowspan="1" colspan="1">EM</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">SBP (mmHg)</td><td align="left" valign="top" rowspan="1" colspan="1">Pre</td><td align="center" valign="top" rowspan="1" colspan="1">126.1 &#x000b1; 3.1</td><td align="center" valign="top" rowspan="1" colspan="1">134.0 &#x000b1; 3.8</td><td align="center" valign="top" rowspan="1" colspan="1">136.8 &#x000b1; 2.4</td><td align="center" valign="top" rowspan="1" colspan="1">126.8 &#x000b1; 5.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Post</td><td align="center" valign="top" rowspan="1" colspan="1">134.5 &#x000b1; 5.4<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">123.9 &#x000b1; 2.7<xref ref-type="table-fn" rid="TFN3">*</xref><xref ref-type="table-fn" rid="TFN4">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">128.0 &#x000b1; 3.9<xref ref-type="table-fn" rid="TFN4">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">126.3 &#x000b1; 5.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">6.5 &#x000b1; 2.7<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;7.3 &#x000b1; 2.0<xref ref-type="table-fn" rid="TFN4">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;6.3 &#x000b1; 3.1<xref ref-type="table-fn" rid="TFN4">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">0.0 &#x000b1; 3.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DBP (mmHg)</td><td align="left" valign="top" rowspan="1" colspan="1">Pre</td><td align="center" valign="top" rowspan="1" colspan="1">76.8 &#x000b1; 2.8</td><td align="center" valign="top" rowspan="1" colspan="1">82.9 &#x000b1; 2.9</td><td align="center" valign="top" rowspan="1" colspan="1">88.1 &#x000b1; 2.1<sup><xref ref-type="table-fn" rid="TFN2">$</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">82.1 &#x000b1; 2.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Post</td><td align="center" valign="top" rowspan="1" colspan="1">82.9 &#x000b1; 2.3<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">78.9 &#x000b1; 1.7<xref ref-type="table-fn" rid="TFN4">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">81.4 &#x000b1; 2.0<xref ref-type="table-fn" rid="TFN4">^</xref><xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">78.5 &#x000b1; 2.5<xref ref-type="table-fn" rid="TFN4">^</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">8.3 &#x000b1; 1.9<xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;4.1 &#x000b1; 3.7<xref ref-type="table-fn" rid="TFN4">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;7.5 &#x000b1; 1.9<xref ref-type="table-fn" rid="TFN4">^</xref><xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.9 &#x000b1; 3.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAP (mmHg)</td><td align="left" valign="top" rowspan="1" colspan="1">Pre</td><td align="center" valign="top" rowspan="1" colspan="1">92.3 &#x000b1; 0.85</td><td align="center" valign="top" rowspan="1" colspan="1">98.9 &#x000b1; 1.2</td><td align="center" valign="top" rowspan="1" colspan="1">103.3 &#x000b1; 0.7</td><td align="center" valign="top" rowspan="1" colspan="1">96.0 &#x000b1; 1.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Post</td><td align="center" valign="top" rowspan="1" colspan="1">99.1 &#x000b1; 1.2</td><td align="center" valign="top" rowspan="1" colspan="1">92.9 &#x000b1; 0.6<xref ref-type="table-fn" rid="TFN4">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">95.9 &#x000b1; 1.0<xref ref-type="table-fn" rid="TFN3">*</xref><xref ref-type="table-fn" rid="TFN4">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">93.3 &#x000b1; 1.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">7.3 &#x000b1; 1.3</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;5.6 &#x000b1; 2.8<xref ref-type="table-fn" rid="TFN4">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;7.1 &#x000b1; 2.1<xref ref-type="table-fn" rid="TFN3">*</xref><xref ref-type="table-fn" rid="TFN4">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2.3 &#x000b1; 3.1</td></tr></tbody></table><table-wrap-foot><p>SBP (systolic blood pressure), DBP (diastolic blood pressure), and MAP (mean arterial pressure).</p><fn id="TFN2"><label>$</label><p id="P31">Significant compared to P at pre-testing. Co-varying for baseline DBP did not alter the results.</p></fn><fn id="TFN3"><label>*</label><p id="P32">Significant compared to baseline; p &#x0003c; 0.05.</p></fn><fn id="TFN4"><label>^</label><p id="P33">Compared to P (p &#x0003c; 0.05).</p></fn><p>Data are mean &#x000b1; standard error of the mean.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float" orientation="landscape"><label>Table 3</label><caption><p>Effect of exercise and/or metformin on blood lipids and inflammation.</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Condition</th><th align="left" valign="top" rowspan="1" colspan="1">Test</th><th align="center" valign="top" rowspan="1" colspan="1">P</th><th align="center" valign="top" rowspan="1" colspan="1">M</th><th align="center" valign="top" rowspan="1" colspan="1">EP</th><th align="center" valign="top" rowspan="1" colspan="1">EM</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">TC (mM)</td><td align="left" valign="top" rowspan="1" colspan="1">Pre</td><td align="center" valign="top" rowspan="1" colspan="1">4.43 &#x000b1; 0.22</td><td align="center" valign="top" rowspan="1" colspan="1">4.76 &#x000b1; 0.31</td><td align="center" valign="top" rowspan="1" colspan="1">4.86 &#x000b1; 0.25</td><td align="center" valign="top" rowspan="1" colspan="1">4.85 &#x000b1; 0.48</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Post</td><td align="center" valign="top" rowspan="1" colspan="1">4.51 &#x000b1; 0.17</td><td align="center" valign="top" rowspan="1" colspan="1">4.48 &#x000b1; 0.35</td><td align="center" valign="top" rowspan="1" colspan="1">4.68 &#x000b1; 0.26</td><td align="center" valign="top" rowspan="1" colspan="1">4.49 &#x000b1; 0.34</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">3.5 &#x000b1; 6.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;5.4 &#x000b1; 5.0</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.7 &#x000b1; 2.4</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;5.5 &#x000b1; 3.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL (mM)</td><td align="left" valign="top" rowspan="1" colspan="1">Pre</td><td align="center" valign="top" rowspan="1" colspan="1">2.33 &#x000b1; 0.21</td><td align="center" valign="top" rowspan="1" colspan="1">2.18 &#x000b1; 0.41</td><td align="center" valign="top" rowspan="1" colspan="1">2.13 &#x000b1; 0.13</td><td align="center" valign="top" rowspan="1" colspan="1">2.4 &#x000b1; 0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Post</td><td align="center" valign="top" rowspan="1" colspan="1">2.48 &#x000b1; 0.19</td><td align="center" valign="top" rowspan="1" colspan="1">1.92 &#x000b1; 0.27</td><td align="center" valign="top" rowspan="1" colspan="1">2.00 &#x000b1; 0.20</td><td align="center" valign="top" rowspan="1" colspan="1">2.1 &#x000b1; 0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2.1 &#x000b1; 11.8</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.6 &#x000b1; 14.0</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;6.9 &#x000b1; 6.9</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;6.1 &#x000b1; 8.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL (mM)</td><td align="left" valign="top" rowspan="1" colspan="1">Pre</td><td align="center" valign="top" rowspan="1" colspan="1">1.46 &#x000b1; 0.11</td><td align="center" valign="top" rowspan="1" colspan="1">1.50 &#x000b1; 0.11</td><td align="center" valign="top" rowspan="1" colspan="1">1.61 &#x000b1; 0.12</td><td align="center" valign="top" rowspan="1" colspan="1">1.54 &#x000b1; 0.07</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Post</td><td align="center" valign="top" rowspan="1" colspan="1">1.36 &#x000b1; 0.11</td><td align="center" valign="top" rowspan="1" colspan="1">1.68 &#x000b1; 0.13<xref ref-type="table-fn" rid="TFN7">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">1.74 &#x000b1; 0.13<xref ref-type="table-fn" rid="TFN7">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">1.65 &#x000b1; 0.07<xref ref-type="table-fn" rid="TFN5">*</xref><sup><xref ref-type="table-fn" rid="TFN8">$</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;7.1 &#x000b1; 2.5</td><td align="center" valign="top" rowspan="1" colspan="1">13.0 &#x000b1; 7.0</td><td align="center" valign="top" rowspan="1" colspan="1">8.2 &#x000b1; 3.8</td><td align="center" valign="top" rowspan="1" colspan="1">7.6 &#x000b1; 2.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRR</td><td align="left" valign="top" rowspan="1" colspan="1">Pre</td><td align="center" valign="top" rowspan="1" colspan="1">3.11 &#x000b1; 0.20</td><td align="center" valign="top" rowspan="1" colspan="1">3.26 &#x000b1; 0.25</td><td align="center" valign="top" rowspan="1" colspan="1">3.10 &#x000b1; 0.21</td><td align="center" valign="top" rowspan="1" colspan="1">3.22 &#x000b1; 0.37</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Post</td><td align="center" valign="top" rowspan="1" colspan="1">3.43 &#x000b1; 0.24</td><td align="center" valign="top" rowspan="1" colspan="1">2.70 &#x000b1; 0.15<xref ref-type="table-fn" rid="TFN7">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">2.79 &#x000b1; 0.24<xref ref-type="table-fn" rid="TFN5">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">2.77 &#x000b1; 0.25<xref ref-type="table-fn" rid="TFN5">*</xref><xref ref-type="table-fn" rid="TFN7">^</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">11.1 &#x000b1; 5.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;14.3 &#x000b1; 6.4</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;10.3 &#x000b1; 3.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;11.8 &#x000b1; 4.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TAG (mM)<sup><xref ref-type="table-fn" rid="TFN6">&#x003c8;</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">Pre</td><td align="center" valign="top" rowspan="1" colspan="1">1.40 &#x000b1; 0.18</td><td align="center" valign="top" rowspan="1" colspan="1">2.36 &#x000b1; 0.40</td><td align="center" valign="top" rowspan="1" colspan="1">2.45 &#x000b1; 0.25</td><td align="center" valign="top" rowspan="1" colspan="1">1.93 &#x000b1; 0.36</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Post</td><td align="center" valign="top" rowspan="1" colspan="1">1.46 &#x000b1; 0.16</td><td align="center" valign="top" rowspan="1" colspan="1">1.92 &#x000b1; 0.28</td><td align="center" valign="top" rowspan="1" colspan="1">2.05 &#x000b1; 0.29</td><td align="center" valign="top" rowspan="1" colspan="1">1.63 &#x000b1; 0.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">3.1 &#x000b1; 11.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;13.8 &#x000b1; 7.3</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;13.5 &#x000b1; 10.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;12.0 &#x000b1; 7.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hs-CRP (ng/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">Pre</td><td align="center" valign="top" rowspan="1" colspan="1">90.2 &#x000b1; 20.8</td><td align="center" valign="top" rowspan="1" colspan="1">100.4 &#x000b1; 19.3</td><td align="center" valign="top" rowspan="1" colspan="1">72.0 &#x000b1; 19.9</td><td align="center" valign="top" rowspan="1" colspan="1">64.0 &#x000b1; 17.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Post</td><td align="center" valign="top" rowspan="1" colspan="1">114.3 &#x000b1; 33.2</td><td align="center" valign="top" rowspan="1" colspan="1">94.5 &#x000b1; 30.2<sup><xref ref-type="table-fn" rid="TFN8">$</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">55.7 &#x000b1; 22.0<xref ref-type="table-fn" rid="TFN5">*</xref><xref ref-type="table-fn" rid="TFN7">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">58.5 &#x000b1; 15.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x00394; (%)</td><td align="center" valign="top" rowspan="1" colspan="1">16.4 &#x000b1; 14.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;20.1 &#x000b1; 18.7<sup><xref ref-type="table-fn" rid="TFN8">$</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;27.4 &#x000b1; 8.7<xref ref-type="table-fn" rid="TFN5">*</xref><xref ref-type="table-fn" rid="TFN7">^</xref></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;8.4 &#x000b1; 10.8</td></tr></tbody></table><table-wrap-foot><p>TC (total cholesterol), LDL (low-density lipoprotein), HDL, (high density lipoprotein), TAG (triacylglycerol), hs-CRP (high sensitive C-reactive protein), CRR (cardiac risk ratio = TC/HDL). &#x00394; = Post- Pre change.</p><fn id="TFN5"><label>*</label><p id="P34">Significant compared to baseline; p &#x0003c; 0.05.</p></fn><fn id="TFN6"><label>&#x003c8;</label><p id="P35">Significant effect of test; p &#x0003c; 0.05.</p></fn><fn id="TFN7"><label>^</label><p id="P36">Compared to P (p &#x0003c; 0.05).</p></fn><fn id="TFN8"><label>$</label><p id="P37">Compared to P (p =0.06).</p></fn><p>Data are mean &#x000b1; standard error of the mean.</p></table-wrap-foot></table-wrap></floats-group></article>